These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22514793)

  • 21. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.
    Chen CC; Wei ST; Tsaia SC; Chen XX; Cho DY
    Br J Neurosurg; 2013 Dec; 27(6):803-7. PubMed ID: 23656173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.
    Mielke R; Möller HJ; Erkinjuntti T; Rosenkranz B; Rother M; Kittner B
    Alzheimer Dis Assoc Disord; 1998; 12 Suppl 2():S29-35. PubMed ID: 9769027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of prolonged therapy of vascular dementia].
    Klin Med (Mosk); 2011; 89(5):57-60. PubMed ID: 22242270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic results with Cerebrolysin in the treatment of dementia.
    Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H
    Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [4th International Symposium. "Cerebrolysin: pharmacological effects and role in clinical practice"].
    Gomazkov OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):69-70. PubMed ID: 12378888
    [No Abstract]   [Full Text] [Related]  

  • 26. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated recovery from acute brain injuries: clinical efficacy of neurotrophic treatment in stroke and traumatic brain injuries.
    Bornstein N; Poon WS
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():43-61. PubMed ID: 22514794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
    Gauthier S; Ferris S
    Int J Clin Pract Suppl; 2001 May; (120):29-39. PubMed ID: 11406924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trials in dementia with propentofylline.
    Kittner B; Rössner M; Rother M
    Ann N Y Acad Sci; 1997 Sep; 826():307-16. PubMed ID: 9329701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury.
    Zhang Y; Chopp M; Meng Y; Zhang ZG; Doppler E; Mahmood A; Xiong Y
    J Neurosurg; 2013 Jun; 118(6):1343-55. PubMed ID: 23581594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
    Vereshchagin NV; Suslina ZA; Timerbaeva SL; Kashina EM; Gnezditskiĭ VV; Maksimova MIu; Rebrova OIu; Smirnova IN
    Ter Arkh; 2001; 73(4):22-7. PubMed ID: 11494441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cerebrolysin in neurological and psychiatric practice].
    Vilenskiĭ BS
    Lik Sprava; 1997; (6):139-42. PubMed ID: 9589960
    [No Abstract]   [Full Text] [Related]  

  • 33. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.
    Rüther E; Ritter R; Apecechea M; Freytag S; Gmeinbauer R; Windisch M
    J Neural Transm (Vienna); 2000; 107(7):815-29. PubMed ID: 11005546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.
    Bornstein NM; Guekht A; Vester J; Heiss WD; Gusev E; Hömberg V; Rahlfs VW; Bajenaru O; Popescu BO; Muresanu D
    Neurol Sci; 2018 Apr; 39(4):629-640. PubMed ID: 29248999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment].
    Gavrilova SI; Kolykhalov IV; Fedorova IaB; Selezneva ND; Kalyn IaB; Roshchina IF; Odinak MM; Emelin AIu; Kashin AV; Gustov AV; Antipenko EA; Korshunova IuA; Davydova TA; Messler G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(1):62-9. PubMed ID: 20436440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current conceptions of neurocytoprotective therapy].
    Gomazkov OA; Afanas'ev VV; Rumiantseva SA; Stupin VA; Silina EV; Sokhova OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12 Pt 2):58-63. PubMed ID: 22792751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.
    Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E
    J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experience with using high doses of cerebrolysin in vascular dementia].
    Iakhno NN; Damulin IV; Zakharov VV; Levin OS; Elkin MN
    Ter Arkh; 1996; 68(10):65-9. PubMed ID: 9026950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].
    Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.